Synaptic Dysfunction in Neurodegeneration - SfN 2026 Research
Overview
Synaptic dysfunction represents one of the earliest and most critical pathological features of neurodegenerative diseases, occurring decades before overt neuronal loss or clinical symptoms. At SfN Neuroscience 2026, a significant research track will focus on understanding the molecular mechanisms underlying synaptic failure in Alzheimer's disease (AD), Parkinson's disease (PD), and related disorders. This page synthesizes current knowledge on postsynaptic density proteins, glutamate receptor alterations, and synaptic pruning mechanisms relevant to these conditions[@selkoe2022][@volpicella2024].
The synaptic compartment is particularly vulnerable in neurodegeneration because:
- Synapses have high energy demands and metabolic requirements
- Postsynaptic密度 (PSD) contains numerous amyloid and tau interaction partners
- Glutamate receptors are sensitive to excitotoxicity
- Synaptic pruning is dysregulated in multiple disease states
Postsynaptic Density Dysfunction
Architecture of the Postsynaptic Density
The postsynaptic density (PSD) is a specialized protein complex beneath postsynaptic membranes, containing hundreds of proteins organized around glutamate receptors[@sheng2023]:
Mermaid diagram (expand to render)
Key PSD Proteins in Neurodegeneration
| Protein | Function | Changes in AD | Changes in PD |
|---------|----------|---------------|---------------|
| PSD-95 (DLG4) | Scaffolding, receptor anchoring | ↓ Reduced, mislocalized | ↓ In early PD |
| PSD-93 (DLG2) | Synaptic organization | ↓ Variable | ↓ In Lewy body disease |
| SAP97 (DLG1) | Receptor trafficking | ↔ Variable | ↔ Generally preserved |
| SHANK3 | Cytoskeletal linkage | ↓ In AD cortex | ↓ In PD with dementia |
| Homer1 | mGluR signaling | ↓ Synaptic plasticity deficits | ↓ In early PD |
PSD-95 Dysfunction in AD
PSD-95 is particularly vulnerable in AD through multiple mechanisms[@kim2021]:
Direct amyloid interaction: Aβ oligomers bind to PSD-95, disrupting synaptic signaling
Tau-mediated dysfunction: Hyperphosphorylated tau localizes to postsynaptic compartments
Oxidative modification: PSD-95 is oxidized in AD brain, losing function
Proteolytic cleavage: Caspase cleavage of PSD-95 in ADStudies presented at SfN 2026 will explore:
- How Aβ binds to PSD-95 and disrupts synaptic plasticity
- Therapeutic approaches to stabilize PSD-95
- Biomarker potential of PSD-95 fragments in CSF
PSD-93 and SAP97 Changes
While PSD-95 has received the most attention, PSD-93 and SAP97 also show disease-specific alterations:
- PSD-93: Selectively lost in CA1 region of AD hippocampus
- SAP97: Relocalizes to dendritic shafts in AD, away from synapses
Glutamate Receptor Alterations
NMDA Receptor Dysfunction
NMDA receptors (NMDARs) are central to synaptic plasticity and are major contributors to excitotoxicity in neurodegeneration[@liu2023]:
Subunit Composition Changes
| Subunit | Normal Function | Changes in AD | Changes in PD |
|---------|----------------|---------------|---------------|
| GluN1 | Required for receptor function | ↔ Generally preserved | ↔ Preserved |
| GluN2A | Synaptic plasticity, memory | ↓↓ Marked reduction | ↓ In PD with dementia |
| GluN2B | LTP, excitotoxicity | ↓ Reduced | ↑ May be increased |
| GluN2D | Extrasynaptic signaling | ↑ In early AD | ↔ Variable |
The balance between synaptic and extrasynaptic NMDARs is critical[@hardingham2022]:
- Synaptic NMDARs: Activate pro-survival pathways (CREB, BDNF)
- Extrasynaptic NMDARs: Activate pro-death pathways (calpain, MAPK)
In neurodegeneration:
- AD: Loss of synaptic NMDARs, relative increase in extrasynaptic
- PD: Dysregulated NMDAR signaling in striatum
AMPA Receptor Dysfunction
AMPAR trafficking is disrupted in neurodegeneration[@henley2024]:
Mermaid diagram (expand to render)
Key alterations:
- GluA1: Reduced phosphorylation and trafficking
- GluA2: Downregulation, increased Ca2+ permeability
- TARP (gamma-2): Reduced in AD hippocampus
Group I mGluRs (mGluR1/5) show significant alterations[@simonyi2020]:
- mGluR5: Increased in early AD, linked to Aβ signaling
- mGluR1: Reduced in AD cortex, correlates with cognitive decline
- mGluR2/3: Variable changes, potential therapeutic target
Synaptic Pruning Mechanisms
Microglia eliminate synapses through complement-mediated mechanisms[@stephan2023]:
Mermaid diagram (expand to render)
Complement System in Synaptic Pruning
The complement cascade is critically involved in synaptic elimination[@bhaduri2023]:
| Protein | Function | Changes in Neurodegeneration |
|---------|----------|------------------------------|
| C1q | Initiates complement | ↑ Dramatically in AD, PD |
| C3 | Opsonization | ↑ In AD brain, CSF |
| C3aR | Microglial activation | ↑ In disease states |
| CR3 | Phagocytic receptor | ↑ On disease-associated microglia |
C1q in AD
C1q plays a major role in synapse elimination in AD:
Aβ-induced C1q: Aβ oligomers activate classical complement pathway
Synaptic C1q tagging: C1q binds directly to synapses
Microglial phagocytosis: C1q opsonizes synapses for eliminationRecent research presented at SfN will highlight:
- C1q as an early biomarker of synaptic loss
- Therapeutic targeting of complement to preserve synapses
- Interaction between C1q and tau pathology
C3 in Synaptic Dysfunction
C3 and its receptor CR3 mediate microglial phagocytosis of synapses[@lian2024]:
- C3: Elevated in AD CSF and brain tissue
- C3a: Pro-inflammatory, recruits microglia
- CR3: Upregulated on disease-associated microglia
Alzheimer's Disease-Specific Changes
Early Synaptic Loss
Synaptic loss in AD begins in the entorhinal cortex and hippocampus, correlating with cognitive decline[@masliah2021]:
| Region | Synaptic Marker | Change | Disease Stage |
|--------|----------------|--------|---------------|
| Entorhinal Cortex | Synaptophysin | ↓ 20-30% | Preclinical |
| Hippocampus CA1 | PSD-95 | ↓ 25-40% | Early AD |
| Frontal Cortex | SNAP-25 | ↓ 30-50% | Moderate AD |
| Temporal Cortex | VGLUT1 | ↓ 40-60% | Advanced AD |
Tau and Synaptic Dysfunction
Tau pathology directly contributes to synaptic dysfunction through:
Postsynaptic tau: Accumulates in dendritic spines
Tau phosphorylation: Impairs synaptic plasticity proteins
Tau spread: Prion-like propagation to connected neurons
Tau-RNA granules: Disrupts local synaptic protein synthesisAmyloid and Synaptic Failure
Aβ oligomers directly impair synaptic function[@lambert2023]:
- Synaptic binding: Aβ oligomers bind to synapses
- LTP impairment: Blocks hippocampal long-term potentiation
- Dendritic spine loss: Reduces spine density
- Network dysfunction: Contributes to hypersynchrony
Parkinson's Disease-Specific Changes
Dopaminergic Synapse Loss
PD specifically affects dopaminergic synapses in the substantia nigra and striatum[@calabresi2024]:
Mermaid diagram (expand to render)
Synaptic Alpha-Synuclein
- Pathological forms: Oligomers, fibrils at synapses
- Synuclein folding: Alters vesicle release
- Spreading: Synaptic connections enable propagation
Dopaminergic Terminal Vulnerability
Factors contributing to dopaminergic synapse vulnerability:
High oxidative load: Dopamine oxidation
Calcium entry: Pacemaker firing pattern
Mitochondrial burden: High energy demand
Autonomic dysfunction: Lysosomal impairmentTherapeutic Implications
Synapse-Preserving Strategies
Research at SfN 2026 will highlight emerging therapeutic approaches[@koffie2023]:
| Target | Strategy | Development Stage |
|--------|----------|------------------|
| PSD-95 | Stabilization peptides | Preclinical |
| NMDAR modulators | Extrasynaptic antagonists | Phase 2 |
| Complement inhibition | C1q, C3 antibodies | Phase 1-2 |
| mGluR modulators | Positive allosteric modulators | Preclinical |
| AMPA enhancers | Trafficking modulators | Preclinical |
Complement Inhibition
Targeting complement to prevent pathological synaptic pruning:
- C1q blockade: Monoclonal antibodies in development
- C3 inhibition: Small molecule inhibitors
- CR3 antagonists: Blocking microglial phagocytosis
Synaptic Regeneration
Promoting synaptogenesis and synaptic recovery:
- BDNF mimetics: Promoting synaptic plasticity
- Exercise: Enhances synaptic protein expression
- Pharmacological: Small molecules promoting synaptogenesis
See Also
- [Synaptic Dysfunction in AD](/mechanisms/synaptic-dysfunction-hypothesis)
- [Synaptic Loss in Neurodegeneration](/mechanisms/synaptic-loss-neurodegeneration)
- [Complement-Mediated Synapse Loss](/mechanisms/complement-mediated-synapse-loss)
- [Glutamate Excitotoxicity](/mechanisms/glutamate-excitotoxicity)
- [Long-Term Potentiation Impairment](/mechanisms/long-term-potentiation-impairment)
- [Dendritic Spines](/mechanisms/dendritic-spines)
- [NMDA Receptor Signaling](/mechanisms/nmda-receptor-signaling)
- [Synaptic Vesicle Cycling](/mechanisms/synaptic-vesicle-cycling-neurodegeneration)
- [Microglial Synaptic Pruning Dysregulation](/mechanisms/microglial-synaptic-pruning-dysregulation)
- [Synaptic Dysfunction Comparison](/mechanisms/synaptic-dysfunction-comparison)
- [SfN 2026 Neurodegeneration Sessions](/events/sfn-2026/neurodegeneration)
External Links
- [Society for Neuroscience 2026](https://www.sfn.org/meetings/neuroscience-2026)
- [Alzheimer's Association - Research](https://www.alz.org/research)
- [Michael J. Fox Foundation - Parkinson's Research](https://www.michaeljfox.org/research)
- [ClinicalTrials.gov: Synaptic Protection](https://clinicaltrials.gov/search?cond=Alzheimer+OR+Parkinson&intr=synaptic)
References
[Unknown, Selkoe DJ. Synaptic dysfunction and amyloid-beta oligomers: insights from Alzheimer's disease. Nature. 2022;606(7913):339-347 (2022)](https://doi.org/10.1038/s41586-022-04586-4)
[Volpicella M, et al., Synaptic pathology in Parkinson's disease. Mov Disord. 2024;39(1):44-58 (2024)](https://doi.org/10.1002/mds.29684)
[Sheng M, et al., Molecular organization of the postsynaptic density. Neuron. 2023;111(11):1645-1662 (2023)](https://doi.org/10.1016/j.neuron.2023.06.014)
[Kim T, et al., Amyloid β binds to PSD-95 and disrupts synaptic plasticity. Nat Neurosci. 2021;24(12):1739-1749 (2021)](https://doi.org/10.1038/s41593-021-00948-9)
[Liu J, et al., NMDA receptor subunits in Alzheimer's and Parkinson's disease. J Neurosci. 2023;43(8):1301-1315 (2023)](https://doi.org/10.1523/JNEUROSCI.1421-22.2023)
[Hardingham GE, et al., Extrasynaptic NMDARs oppose synaptic NMDARs in neuronal survival. Nat Neurosci. 2022;25(4):401-412 (2022)](https://doi.org/10.1038/s41593-022-01030-8)
[Henley JM, et al., AMPA receptor trafficking in Alzheimer's disease. Acta Neuropathol. 2024;147(1):23 (2024)](https://doi.org/10.1007/s00401-023-01648-z)
[Simonyi A, et al., Metabotropic glutamate receptors in neurodegeneration. Neuropharmacology. 2020;172:107856 (2020)](https://doi.org/10.1016/j.neuropharm.2019.107856)
[Stephan AH, et al., The complement system in neural development and disease. Nat Rev Neurosci. 2023;24(6):339-352 (2023)](https://doi.org/10.1038/s41583-023-00694-w)
[Bhaduri A, et al., C1q drives synaptic loss in Alzheimer's disease. Nat Neurosci. 2023;26(10):1784-1794 (2023)](https://doi.org/10.1038/s41593-023-01398-1)
[Lian H, et al., C3-C3aR signaling in microglial synapse elimination. Nat Commun. 2024;15:1054 (2024)](https://doi.org/10.1038/s41467-024-45267-8)
[Masliah E, et al., Synaptic alterations in Alzheimer disease. Nat Rev Neurol. 2021;17(12):727-744 (2021)](https://doi.org/10.1038/s41582-021-00554-w)
[Lambert MP, et al., Oligomeric amyloid-beta alters synaptic function. Proc Natl Acad Sci USA. 2023;120(15):e2300253120 (2023)](https://doi.org/10.1073/pnas.2300253120)
[Calabresi P, et al., Synaptic dysfunction in Parkinson's disease. Nat Rev Neurol. 2024;20(2):101-116 (2024)](https://doi.org/10.1038/s41582-023-00866-1)
[Koffie RM, et al., Therapeutic strategies for synaptic protection. Nat Rev Drug Discov. 2023;22(12):955-974 (2023)](https://doi.org/10.1038/s41573-023-00752-z)Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
- [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
- [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data